Cost and Value in Contemporary Heart Failure Clinical Guidance Documents

John W. Ostrominski, MD; Sameer Hirji, MD, MPH; Ankeet S. Bhatt, MD, MBA; Javed Butler, MD, MPH, MBA; Mona Fiuzat, PHARMD; Gregg C. Fonarow, MD; Paul A. Heidenreich, MD, MS; James L. Januzzi, JR, MD; Carolyn S.P. Lam, MBBS, PHD; Thomas M. Maddox, MD, MS; Christopher M. O'Connor, MD; Muthiah Vaduganathan, MD, MPH


JACC Heart Fail. 2022;10(1):1-11. 

In This Article


Although most contemporary HF CGDs contain at least 1 cost/value statement, these CGDs have generally focused on the economic impact of HF, with less explicit consideration of cost/value in clinical guidance recommendations. To promote cost-sensitivity and value-based care efforts, we propose potential opportunities for future HF-focused CGDs.